Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children.
AIM: To evaluate the long-term safety and effectiveness of lopinavir/ritonavir (LPV/r) in a population-based cohort of HIV-1-infected children. METHODS: All children enrolled in the Swiss Mother and Child HIV Cohort Study, treated with LPV/r-based combination antiretroviral treatment (cART) between...
| Main Authors: | , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2010
|
| _version_ | 1797053643583651840 |
|---|---|
| author | Rudin, C Wolbers, M Nadal, D Rickenbach, M Bucher, H |
| author_facet | Rudin, C Wolbers, M Nadal, D Rickenbach, M Bucher, H |
| author_sort | Rudin, C |
| collection | OXFORD |
| description | AIM: To evaluate the long-term safety and effectiveness of lopinavir/ritonavir (LPV/r) in a population-based cohort of HIV-1-infected children. METHODS: All children enrolled in the Swiss Mother and Child HIV Cohort Study, treated with LPV/r-based combination antiretroviral treatment (cART) between November 2000 and October 2008, were included. RESULTS: 88 children (25 (28%) protease inhibitor (PI)-naive, 16 (18%) ART-naive) were analysed (251 patient-years on LPV/r). After 48 weeks on LPV/r, 70 children had a median (interquartile range (IQR)) decrease in HIV-1 viral load of 4.25 log (5.45-3.17; PI-naive, n=17) and 2.53 (3.68-1.38; PI-experienced, n=53). Median (IQR) increase in CD4 count was 429 (203-593; PI-naive) and 177 (21-331; PI-experienced) cells/microl. These effects remained stable throughout 192 weeks for 25 children. Treatment was stopped for viral rebound in seven and suspected toxicity in 12 children. CONCLUSION: Long-term treatment with LPV/r-based cART is safe and effective in HIV-1-infected children. |
| first_indexed | 2024-03-06T18:46:33Z |
| format | Journal article |
| id | oxford-uuid:0eb8202f-9688-418e-8492-ef5af8788c31 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T18:46:33Z |
| publishDate | 2010 |
| record_format | dspace |
| spelling | oxford-uuid:0eb8202f-9688-418e-8492-ef5af8788c312022-03-26T09:47:26ZLong-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:0eb8202f-9688-418e-8492-ef5af8788c31EnglishSymplectic Elements at Oxford2010Rudin, CWolbers, MNadal, DRickenbach, MBucher, H AIM: To evaluate the long-term safety and effectiveness of lopinavir/ritonavir (LPV/r) in a population-based cohort of HIV-1-infected children. METHODS: All children enrolled in the Swiss Mother and Child HIV Cohort Study, treated with LPV/r-based combination antiretroviral treatment (cART) between November 2000 and October 2008, were included. RESULTS: 88 children (25 (28%) protease inhibitor (PI)-naive, 16 (18%) ART-naive) were analysed (251 patient-years on LPV/r). After 48 weeks on LPV/r, 70 children had a median (interquartile range (IQR)) decrease in HIV-1 viral load of 4.25 log (5.45-3.17; PI-naive, n=17) and 2.53 (3.68-1.38; PI-experienced, n=53). Median (IQR) increase in CD4 count was 429 (203-593; PI-naive) and 177 (21-331; PI-experienced) cells/microl. These effects remained stable throughout 192 weeks for 25 children. Treatment was stopped for viral rebound in seven and suspected toxicity in 12 children. CONCLUSION: Long-term treatment with LPV/r-based cART is safe and effective in HIV-1-infected children. |
| spellingShingle | Rudin, C Wolbers, M Nadal, D Rickenbach, M Bucher, H Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children. |
| title | Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children. |
| title_full | Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children. |
| title_fullStr | Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children. |
| title_full_unstemmed | Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children. |
| title_short | Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children. |
| title_sort | long term safety and effectiveness of lopinavir ritonavir in antiretroviral experienced hiv 1 infected children |
| work_keys_str_mv | AT rudinc longtermsafetyandeffectivenessoflopinavirritonavirinantiretroviralexperiencedhiv1infectedchildren AT wolbersm longtermsafetyandeffectivenessoflopinavirritonavirinantiretroviralexperiencedhiv1infectedchildren AT nadald longtermsafetyandeffectivenessoflopinavirritonavirinantiretroviralexperiencedhiv1infectedchildren AT rickenbachm longtermsafetyandeffectivenessoflopinavirritonavirinantiretroviralexperiencedhiv1infectedchildren AT bucherh longtermsafetyandeffectivenessoflopinavirritonavirinantiretroviralexperiencedhiv1infectedchildren |